Compare Abeona Therapeutics Inc (ABEO) vs Snap Inc (SNAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Snap Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Snap Inc trades at $4.58 (market cap $7.71B). The key difference: Snap Inc is far larger — about 20.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SNAP | |
|---|---|---|
Market Cap | $373.32M | $7.71B |
Sector | Health | Media |
52-Week High | $7.23 | $10.35 |
52-Week Low | $4.17 | $3.93 |
Enterprise Value | $228.22M | $9.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Snap Inc. (SNAP) trades at $4.65, down 4.12% on the day, reflecting investor concerns over its recent launch of high-priced AR glasses. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, revenue grew to $5.93 billion in 2025, yet the company remains unprofitable with a net loss of $460 million. Analyst sentiment is cautious, with a consensus price target of $7.22 but a majority hold rating.
Snap's outlook hinges on monetizing its augmented reality initiatives and achieving sustained user growth, but execution risks and competitive pressures from larger peers like Meta pose significant challenges. The stock offers speculative upside if new hardware gains traction, yet persistent losses and regulatory scrutiny over social media safety present substantial downside risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
